Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID-19 Infection.

Clin Pharmacol Ther · 2021 · PMC8652670 · PMID 34514598

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The viral load reduction was highly significant and could be as much as a 93% reduction relative to placebo if the drugs are administered 1 day after the onset of symptoms.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.